Afromics provides ethically sourced African genomic, clinical, and phenotypic data to healthcare systems, researchers, CROs, and pharmaceutical companies, enabling more accurate diagnoses, personalized treatments, and inclusive drug discovery. By partnering with local communities and adhering to strict data sovereignty standards, they help reduce adverse drug reactions and improve clinical trial design, starting with sickle cell disease as a primary focus.
Funding
Funding not disclosed
Founders
Product
Problem
African populations are underrepresented in genomic databases, leading to inaccurate diagnoses, higher adverse drug reactions, and limited relevance of precision‑medicine research for patients of African ancestry.
Solution
Afromics aggregates ethically sourced African genomic, clinical, and phenotypic data and makes it available to healthcare systems, researchers, CROs, and pharmaceutical companies. The platform co‑designs studies with local communities, returns individual genetic reports, and implements benefit‑sharing mechanisms to ensure tangible health improvements. Strict data‑sovereignty governance protects participant privacy while granting communities ownership of their data. By focusing initially on sickle‑cell disease, Afromics provides population‑specific insights that reduce treatment failures and support the development of targeted therapies. The curated dataset enables more accurate diagnosis, personalized treatment plans, and inclusive drug discovery across the African continent.
Target Audience
Primary customers are African healthcare providers, academic and industry researchers, contract research organizations, and pharmaceutical companies seeking high‑quality, ethically sourced African genomic data for diagnosis, treatment, and drug development.
Features
- Community‑co‑designed study protocols with transparent benefit‑sharing and return of genetic reports
- Independent ethics advisory board overseeing bioethical compliance and community engagement
- Strict data‑sovereignty framework that enforces participant privacy and community ownership
- Integrated genomic, clinical, and phenotypic datasets from Africa’s highly diverse founder populations
- Tools for healthcare systems to implement ancestry‑informed diagnostics, screening, and adverse‑drug‑reaction mitigation
- Resources for CROs to improve patient recruitment, ancestry‑stratified trial design, and regulatory submissions
- Access for pharmaceutical companies to ethically sourced data that accelerates population‑specific drug discovery